Risk factor
Limited trading liquidity
Profitability factor
Strong margins and returns
About
Founded in 2001 and headquartered in Vantaa, Finland, Revenio Group Oyj operates as a health technology firm. This company specializes in developing, manufacturing, and distributing advanced ophthalmic diagnostic equipment and devices. These solutions are crucial for identifying and managing prevalent eye conditions such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts, serving clients in Finland, across Europe, and worldwide. Their comprehensive product portfolio includes the iCare IC100 and IC200 tonometers, alongside the iCare HOME, an innovative device enabling patients to self-monitor their eye pressure. For advanced imaging, Revenio provides the iCare EIDON AF, which delivers confocal retinal imaging; the DRSplus, specifically designed for the detection of diabetic retinopathy; the iCare MAIA, a microperimeter used for precise visual field measurement; and the iCare COMPASS, facilitating fundus perimetry coupled with true-color confocal retinal images. Beyond hardware, the company also offers Oculo, a sophisticated eye care software platform. This platform seamlessly integrates functionalities for clinical communication, telehealth services, remote patient monitoring, and sophisticated data analytics.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value
Target Price
The average target price of REG1V.HE is 19 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr